Custom Report

La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise. Target or technology pipeline and corporate benchmark analysis and assessment reports can be prepared according to the specifications of the client from the pharmaceutical or biotechnology industry.

More info

BAGSVAERD, Denmark I June 26, 2015 I Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the expanded use of Levemir® (insulin detemir) in children with diabetes as young as one year old.

There are an estimated 497,100 children living with type 1 diabetes globally and incidence is increasing in many countries1. Young children with type 1 diabetes can be difficult to treat as their needs are in constant flux during growth and development2, with children aged six and under at greatest risk of severe hypoglycaemia and acute diabetes complications3.

References

  1. International Diabetes Federation. Diabetes Atlas, sixth edition. The global burden. Available at: http://www.idf.org/sites/default/files/EN_6E_Ch2_the_Global_Burden.pdf. Last accessed: May 2015.
  2. Thalange N, et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatric Diabetes. 2015;16:164-176.
  3. Rewers A, et al. Predictors of acute complications in children with type 1 diabetes. JAMA. 2002;287:2511-2518.

Read the full release in PDF

SOURCE: Novo Nordisk

Post Views: 141